Patients who identified a dose that produced satisfactory PR for at least two target breakthrough pain episodes were eligible to enter the double-blind crossover period.
Long-acting oral morphine was used in 23.8% of patients for persistent pain and short-acting oral morphine was used in 26.5% of patients for target breakthrough pain.
The most common stable opioid regimen was transdermal fentanyl for persistent pain, taken by 46.4% of patients, and hydrocodone for target breakthrough pain, taken by 42.4% of patients.
For approximately half of the patients in the safety population, the pain pathophysiology for both persistent pain and target breakthrough pain was somatic and/or visceral.
Any subsequent dose of study medication was for the emergence of a new target breakthrough pain episode and not an unresolved previously treated episode.
For most patients in the safety population, the pain syndrome for persistent and target breakthrough pain was typically related to direct tumor involvement (84.8% and 86.1% of patients, respectively) or due to somatic/visceral lesions (83.4% and 84.8% of patients, respectively).
The awakening and growth of micrometastatic cells therefore is the committed step in metastasis, and if such suppressed cells could be targeted effectively, a breakthrough in cancer therapy could result.
In our cohort, primary AVF creation in association with a high secondary AVF rate led to prevalent AVF and non-PC use rates persistently over those targeted by the Fistula First Breakthrough Initiative and the UK BPT [ 7, 8].
The pathway of drug discovery from gene and therapeutic targets to breakthrough medicines provides an extraordinary adventure that often includes high risks, creative insights, relentless perserverance, goal-oriented focus, interdisciplinary teamwork and a bit of good luck.
The first frontier for this breakthrough may be oncology where such targeted drug delivery is obvious.
